M
Malcolm J. Moore
Researcher at Princess Margaret Cancer Centre
Publications - 238
Citations - 45832
Malcolm J. Moore is an academic researcher from Princess Margaret Cancer Centre. The author has contributed to research in topics: Gemcitabine & Cancer. The author has an hindex of 64, co-authored 231 publications receiving 42222 citations. Previous affiliations of Malcolm J. Moore include University Health Network & Ontario Institute for Cancer Research.
Papers
More filters
UROLOGICAL ONCOLOGY: BLADDER, PENIS AND URETHRA CANCER, AND BASIC PRINCIPLES OF ONCOLOGY Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine Plus Cisplatin, With Methotrexate, Vinblastine, Doxorubicin, Plus Cisplatin in Patients With Bladder Cancer
H. von der Maase,Lisa Sengeløv,J. T. Roberts,Sergio Ricci,Luigi Dogliotti,Tim Oliver,Malcolm J. Moore,Annamaria Zimmermann,M. Arning +8 more
Journal ArticleDOI
Phase I-II study of 5-fluorouracil, leucovorin, doxorubicin, methotrexate, and long-term oral etoposide (FLAME) in unresectable or metastatic gastric cancer.
Georg A. Bjarnason,C. Cripps,Rakesh Goel,S. Fine,Amit M. Oza,J. Skillings,Ian G. Kerr,Colin Germond,Malcolm J. Moore,Jean A. Maroun,Edmee Franssen,Helene Dulude +11 more
TL;DR: The objective response rate and median survival for the combined group is comparable with that reported for the etoposide, leucovorin, and 5-fluorouracil and methotrexate regimens in a recently reported, multicenter, phase III study.
Journal ArticleDOI
Phase II trial of neoadjuvant full-dose gemcitabine, oxaliplatin, and radiation (RT) in patients with resectable (R) or borderline resectable (BR) pancreatic cancer.
Ellen J. Kim,Edgar Ben-Josef,Kent A. Griffith,Joseph M. Herman,Christopher L. Wolfgang,Tanios Bekaii-Saab,Mark Bloomston,Laura A. Dawson,Malcolm J. Moore,Mark M. Zalupski +9 more
TL;DR: Neoadjuvant therapy with full dose gem, ox and RT was possible in a large proportion of pts with localized pancreas cancer and resulted in a high percentage of R0 resections.
Journal ArticleDOI
49 Prognostic factors in stage I seminoma managed by surveillance
Padraig Warde,Mary Gospodarowicz,Tony Panzarella,D. Banarjee,L. Sugar,Charles Catton,Jeremy Sturgeon,Malcolm J. Moore,Michael Jewett +8 more
Journal ArticleDOI
Predictive and prognostic features of metastatic colorectal cancer arising from the transverse colon: A pooled analysis of the CCTG/AGITG CO.17 and CO.20 randomized trials.
João Paulo Solar Vasconcelos,Nancy P. Chen,Dongsheng Tu,Stephanie Brule,Rachel Anne Goodwin,Derek J. Jonker,Timothy J. Price,John Zalcberg,Malcolm J. Moore,Christos S. Karapetis,Lillian L. Siu,Jeremy Shapiro,John Simes,Chris O’Callaghan,Jonathan M. Loree +14 more
TL;DR: In this article , the authors investigated the predictive and prognostic features of transverse colon primary location in a pooled cohort from these trials and found that left side was predictive of greater Cet benefit and presented better overall prognosis when single agent Cet was used after 5-FU, oxaliplatin and irinotecan.